Study reaffirms use of short term HT for younger women

Investigators from the Women’s Health Initiative (WHI) Hormone Trials are reaffirming conclusions that hormone therapy is not recommended for the prevention of chronic disease, but may remain a reasonable option for the short-term management of menopausal symptoms for younger women. Investigators reached this conclusion after reviewing data from the trial and the extended post-trial follow up period.

Vitamin D Alone does not Boost Bone Health

TUESDAY, Sept. 24 (HealthDay News) -- Calcium supplements improve bone health in postmenopausal women, but vitamin D supplements provide no benefit in women with normal vitamin D levels, a new study finds.
"These findings suggest that vitamin D supplements over the recommended dietary allowance do not protect bone health, whereas calcium supplements do have an effect," study lead author Dr. John Aloia, of Winthrop University Hospital in Mineola, N.Y., said in a news release from the Endocrine Society.

FDA Okays Duavee for Hot Flashes, Osteoporosis

Oct 03, 2013- The US Food and Drug Administration (FDA) today approved a novel estrogen-based drug for women to treat moderate-to-severe vasomotor symptoms associated with menopause as well as prevent postmenopausal osteoporosis, the agency said today.
The new drug for menopausal women (Duavee, Wyeth Pharmaceuticals, a division of Pfizer) is the first to combine conjugated estrogens with bazedoxifene, an estrogen agonist/antagonist. Bazedoxifene reduces the risk for endometrial hyperplasia, a possible precursor to cancer associated with the drug's estrogen component.